MiNK Therapeutics, Inc. announced on July 15, 2025, the publication of a peer-reviewed article in Frontiers in Immunology titled “CAR-iNKT Cells: Redefining the Frontiers of Cellular Immunotherapy.” The article, authored by leading experts, highlights iNKT cells as a next-generation off-the-shelf platform for treating solid tumors.
The publication underscores the unique attributes of iNKT cells, including their ability to home to tumors, dismantle immunosuppressive barriers, and activate other immune cells without requiring lymphodepletion or HLA matching. CEO Jennifer Buell, PhD, emphasized that MiNK’s allogeneic iNKT platform, agenT-797, has already demonstrated potent, durable activity in solid tumors.
The review details how engineered CAR-iNKTs retain innate tumor-homing and immunomodulatory features while gaining antigen-specific precision, offering a dual mechanism of action. MiNK-215, an IL-15–armored, FAP-targeting CAR-iNKT therapy, is designed to penetrate fibrotic, immune-excluded tumors, with preclinical data showing it depletes stromal barriers and enhances T cell infiltration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.